| |
| |
| Exchange: |
N/A |
| Security
Type: |
N/A |
| Shares
Out: |
13,030,000 |
| Market
Cap: |
54.60(M) |
| Last
Volume: |
0 |
Avg
Vol: |
0 |
| 52
Week Range: |
$4.24 - $29.17 |
|
| Level
I Sector: |
N/A |
| Level
II Sector: |
N/A |
| Level
III Sector: |
N/A |
|
Member Indexes:
|
Rankings:
|
|
| Insider 3 Months : - |
| Insider 6 Months : - |
| Insider 3/6 Months : - |
|
| Guru Rank Number : 634 |
| Guru Rank Value : 3 |
| Guru Occurances : 1 |
|
|
|
|
|
| |
|
Company Profile Eagle Pharmaceuticals is a pharmaceutical company focused on developing medicines to treat diseases of the central nervous system or metabolic critical care therapeutic areas as well as in oncology. Co.'s products include: Belrapzo® (bendamustine ready-to-dilute (RTD) 500ml solution), Bendeka® (infused bendamustine RTD) and Treakisym® for chronic lymphocytic leukemia and non-hodgkin's lymphoma; Ryanodex® (dantrolene sodium) for malignant hyperthermia; EP-4104 Ryanodex® (dantrolene sodium) for the treatment of organophosphate exposure; PEMFEXY™ (pemetrexed for injection) for lung cancer; and EA-114 (fulvestrant) for breast cancer.
|
|
|
D/I:
|
|
|
D
is for direct shares.
I is
for indirect shares.
D/I
refers to the Direct or Indirect
shares traded vs. held. |
|
|
|
Forms:
|
|
|
A
Form 4 is a form filed
by an insider to indicate a change
in ownership.
A Form
3 is a form filed by
an insider to indicate an
initial ownership of a security. |
|
|
|
3m +/-:
|
|
|
|
This
represents the company's 3 month
price change. The initial price
is based on the closing price
of the stock on the day the transaction
took place. Purchases & sales
are viewed as long & short
positions respectively.
|
|
|
|
Actions:
|
|
|
| B |
Buy |
| S |
Sell |
| OE |
Option
Exercised |
| A |
Acquired |
| D |
Disposed |
| AB |
Automatic
Buy |
| AS |
Automatic
Sell |
| IO |
Initial
Ownership |
|
|
|
|
Download:
|
|
|
Download only Transactions
Forms. (Default)
Download
only Summary Infomation.
Download
both Transactions and Summary Data
|
|
|
|
|
| |
| |
Summary (Direct Transactions Only)  |
3 Months |
6 Months |
12 Months |
24 Months |
| Total Shares Bought |
0 |
0 |
0 |
0 |
| Total Buy Value |
$0 |
$0 |
$0 |
$0 |
| Total People Bought |
0 |
0 |
0 |
0 |
| Total Buy Transactions |
0 |
0 |
0 |
0 |
| Total Shares Sold |
0 |
0 |
80,245 |
87,045 |
| Total Sell Value |
$0 |
$0 |
$1,530,383 |
$1,741,115 |
| Total People Sold |
0 |
0 |
1 |
2 |
| Total Sell Transactions |
0 |
0 |
6 |
7 |
| End Date |
2024-02-01 |
2023-10-31 |
2023-05-02 |
2022-05-02 |
|
| Filer's Name |
Relation Title |
Off-Dir-10% |
Tran. Date |
Form |
Action |
Price |
Mkt Value |
D/I |
Shares |
Holdings |
Rank
|
|
|
| 3m +/- |
|
|
Form |
  Tarriff Scott |
|
– – • |
2024-02-28 |
4 |
D |
$6.27 |
$13,286 |
D/D |
(2,119) |
460,621 |
|
- |
|
| Cahill Brian Joseph |
CHIEF FINANCIAL OFFICER |
• – – |
2024-02-27 |
4 |
D |
$6.44 |
$10,233 |
D/D |
(1,589) |
47,958 |
|
- |
|
| Cahill Brian Joseph |
CHIEF FINANCIAL OFFICER |
• – – |
2024-02-27 |
4 |
A |
$0.00 |
$0 |
D/D |
3,800 |
49,547 |
|
- |
|
| Tarriff Scott |
|
– – • |
2024-02-27 |
4 |
D |
$6.44 |
$20,312 |
D/D |
(3,154) |
462,740 |
|
- |
|
| Tarriff Scott |
|
– – • |
2024-02-27 |
4 |
A |
$0.00 |
$0 |
D/D |
12,950 |
465,894 |
|
- |
|
| Cahill Brian Joseph |
CHIEF FINANCIAL OFFICER |
• – – |
2024-02-02 |
4 |
D |
$5.85 |
$5,464 |
D/D |
(934) |
45,747 |
|
- |
|
| Tarriff Scott |
|
– – • |
2024-01-05 |
4 |
D |
$5.13 |
$22,172 |
D/D |
(4,322) |
541,125 |
|
- |
|
| Cahill Brian Joseph |
Chief Financial Officer |
• – – |
2024-01-05 |
4 |
D |
$5.13 |
$3,771 |
D/D |
(735) |
46,681 |
|
- |
|
| Cahill Brian Joseph |
Chief Financial Officer |
• – – |
2023-12-18 |
4 |
D |
$4.76 |
$2,152 |
D/D |
(452) |
47,416 |
|
- |
|
| Graves Michael |
Director |
– • – |
2023-10-27 |
4 |
OE |
$4.94 |
$46,238 |
D/D |
9,360 |
10,360 |
|
- |
|
| Tarriff Scott |
CEO |
• • • |
2023-10-03 |
4 |
AS |
$14.41 |
$155,174 |
D/D |
(10,734) |
567,066 |
|
-61% |
|
| Tarriff Scott |
CEO |
• • • |
2023-10-02 |
4 |
AS |
$15.23 |
$144,853 |
D/D |
(9,511) |
577,800 |
|
-65% |
|
| Tarriff Scott |
CEO |
• • • |
2023-05-16 |
4 |
S |
$19.98 |
$299,700 |
D/D |
(15,000) |
587,311 |
|
21% |
|
| Tarriff Scott |
CEO |
• • • |
2023-05-15 |
4 |
S |
$21.06 |
$315,992 |
D/D |
(15,000) |
1,594,934 |
|
25% |
|
| Tarriff Scott |
CEO |
• • • |
2023-05-12 |
4 |
S |
$19.69 |
$304,014 |
D/D |
(15,000) |
1,609,934 |
|
26% |
|
| Tarriff Scott |
CEO |
• • • |
2023-05-11 |
4 |
S |
$20.71 |
$310,650 |
D/D |
(15,000) |
1,624,934 |
|
27% |
|
| Tarriff Scott |
CEO |
• • • |
2023-03-01 |
4 |
A |
$0.00 |
$0 |
D/D |
70,900 |
1,639,934 |
|
- |
|
| Cahill Brian Joseph |
Chief Financial Officer |
• – – |
2023-03-01 |
4 |
A |
$0.00 |
$0 |
D/D |
18,500 |
47,868 |
|
- |
|
| Tarriff Scott |
CEO |
• • • |
2023-02-28 |
4 |
D |
$28.00 |
$87,164 |
D/D |
(3,113) |
1,569,034 |
|
- |
|
| Cahill Brian Joseph |
Chief Financial Officer |
• – – |
2023-02-28 |
4 |
D |
$28.00 |
$20,104 |
D/D |
(718) |
29,368 |
|
- |
|
| Cahill Brian Joseph |
Chief Financial Officer |
• – – |
2023-02-02 |
4 |
D |
$34.09 |
$26,761 |
D/D |
(785) |
30,086 |
|
- |
|
| Cahill Brian Joseph |
Chief Financial Officer |
• – – |
2023-01-30 |
4 |
D |
$33.21 |
$19,959 |
D/D |
(601) |
30,871 |
|
- |
|
| Tarriff Scott |
CEO |
• • • |
2023-01-23 |
4 |
D |
$33.64 |
$125,544 |
D/D |
(3,732) |
1,572,147 |
|
- |
|
| Cahill Brian Joseph |
Chief Financial Officer |
• – – |
2023-01-05 |
4 |
D |
$29.26 |
$21,477 |
D/D |
(734) |
31,472 |
|
- |
|
| Tarriff Scott |
CEO |
• • • |
2023-01-05 |
4 |
D |
$29.26 |
$111,978 |
D/D |
(3,827) |
1,575,879 |
|
- |
|
199 Records found
|
|
Page 1 of 8 |
|
|
| |
Transaction Code Key: |
Ownership Code Key |
| |
B |
- Buy |
AB |
- Automatic Buy |
D |
- Direct Ownership |
| |
S |
- Sell |
AS |
- Automatic Sell |
I |
- Indirect Ownership |
| |
OE |
- Options Exercised |
A |
- Acquired |
| |
IO |
- Initital Ownership |
D |
- Disposed |
| |
|
|
|
|
|
0.10 (2.44%) 
